Efficacy, Safety and Pharmacokinetics of SPK-843 in the Treatment of Pulmonary Mycosis
Status:
Unknown status
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
Recruitment of at least 10 adult patients (men and women) among individuals affected and
admitted to the hospitals identified for the clinical study. All patients shall be between 18
and 75 years of age, with confirmed diagnosis of cryptococcosis or aspergillosis . During
therapy (14 days) and examination (28 days), the patients will be subject to 7 doctor's
visits (day 1,3,7,10,14,21, and 28).